Literature DB >> 24187359

One-stage exchange: it all began here.

T Gehrke1, A Zahar, D Kendoff.   

Abstract

Based on the first implementation of mixing antibiotics into bone cement in the 1970s, the Endo-Klinik has used one stage exchange for prosthetic joint infection (PJI) in over 85% of cases. Looking carefully at current literature and guidelines for PJI treatment, there is no clear evidence that a two stage procedure has a higher success rate than a one-stage approach. A cemented one-stage exchange potentially offers certain advantages, mainly based on the need for only one operative procedure, reduced antibiotics and hospitalisation time. In order to fulfill a one-stage approach, there are obligatory pre-, peri- and post-operative details that need to be meticulously respected, and are described in detail. Essential pre-operative diagnostic testing is based on the joint aspiration with an exact identification of any bacteria. The presence of a positive bacterial culture and respective antibiogram are essential, to specify the antibiotics to be loaded to the bone cement, which allows a high local antibiotic elution directly at the surgical side. A specific antibiotic treatment plan is generated by a microbiologist. The surgical success relies on the complete removal of all pre-existing hardware, including cement and restrictors and an aggressive and complete debridement of any infected soft tissues and bone material. Post-operative systemic antibiotic administration is usually completed after only ten to 14 days.

Entities:  

Keywords:  antibiotic cement; endo clinic; joint aspiration; one staged exchange; periprosthetic infection

Mesh:

Substances:

Year:  2013        PMID: 24187359     DOI: 10.1302/0301-620X.95B11.32646

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  25 in total

Review 1.  [Septic endoprosthesis exchange : Preoperative diagnosis and reimplantation].

Authors:  H M L Mühlhofer; J Schauwecker; I J Banke; R von Eisenhart-Rothe
Journal:  Orthopade       Date:  2015-12       Impact factor: 1.087

Review 2.  Antibiotic-laden PMMA bead chains for the prevention of infection in compound fractures: current state of the art.

Authors:  David Seligson; Stephen Berling
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-06-09

Review 3.  The Role of One-Stage Exchange for Prosthetic Joint Infection.

Authors:  Fiachra E Rowan; Matthew J Donaldson; Jurek R Pietrzak; Fares S Haddad
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

4.  Infection post-total knee replacement: current concepts.

Authors:  Pouya Alijanipour; Javad Parvizi
Journal:  Curr Rev Musculoskelet Med       Date:  2014-06

5.  CORR Insights®: One-stage Revision With Catheter Infusion of Intraarticular Antibiotics Successfully Treats Infected THA.

Authors:  Antonia F Chen
Journal:  Clin Orthop Relat Res       Date:  2016-08-29       Impact factor: 4.176

6.  Preliminary clinical results of coated porous tibia cones in septic and aseptic revision knee arthroplasty.

Authors:  Malte Ohlmeier; Christian Lausmann; Matthias Wolff; Hussein Abdelaziz; Thorsten Gehrke; Mustafa Citak
Journal:  Arch Orthop Trauma Surg       Date:  2020-04-09       Impact factor: 3.067

7.  [Septic arthritis in adults].

Authors:  J Loock; N Haustedt; J Wollenhaupt
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

8.  [Addition of antibiotics to bone cement for septic prosthesis exchange].

Authors:  A Zahar; P Hannah
Journal:  Oper Orthop Traumatol       Date:  2015-09-28       Impact factor: 1.154

9.  Treatment options in PJI - is two-stage still gold standard?

Authors:  Igor Lazic; Christian Scheele; Florian Pohlig; Rüdiger von Eisenhart-Rothe; Christian Suren
Journal:  J Orthop       Date:  2021-01-20

10.  What Is the Mid-term Survivorship of Infected Rotating-hinge Implants Treated with One-stage-exchange?

Authors:  Malte Ohlmeier; Fadi Alrustom; Mustafa Citak; Jochen Salber; Thorsten Gehrke; Jannik Frings
Journal:  Clin Orthop Relat Res       Date:  2021-12-01       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.